Health care cost pressures will increase demand for economic analysis Most pharmacoeconomic departments expect to become more involved in licensing opportunities, compound selection, and research termination decisions. Despite this growing influence, those departments believe senior management lacks appreciation of the strategic role of pharmacoeconomics. The greatest perceived obstacles to conducting pharmacoeconomic studies are conflicting internal priorities, limited resources, and inadequate understanding within the organization of the role of pharmacoeconomics. The demand for pharmacoeconomic analyses conducted by pharmaceutical firms is likely to grow substantially in the near future as managed care providers, pharmacy benefit managers, and foreign pricing and reimbursement authorities increasingly demand credible evidence of pharmaceutical value. This Impact Report summarizes the key findings of this research.
Many departments help formulate clinical trial designs.
Departments are influencing important clinical trial parameters, such as sample size, the countries in which trials are conducted, and indications to be studied. . . . Regulatory heads were thought to have the least understanding of the contribution of pharmacoeconomics. Senior management was often thought to have little or no understanding of the value of pharmacoeconomics to profits. Pharmacoeconomics defined Pharmacoeconomics measures the total costs associated with a disease and compares net costs for interventions that achieve the same outcome. This provides valuable information to health care decision makers, who must allocate resources.